AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report) and keeping the price target at ...

The first notable agency action in 2024 is the FTC’s Second Request in Novo Holding’s proposed $16.5 billion acquisition of Catalent, a life sciences contract manufacturer. 1 The agency’s interest in ...

With that in mind, let's consider two dividend stocks that can help investors get through the toughest recessions: AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). There is a good reason healthcare is ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart ...

We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cancer stocks.